CoChat

Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial

Open access

The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Although older adults commonly take multivitamin-multimineral (MVM) supplements to promote health, evidence on the use of daily MVMs on invasive cancer is limited. OBJECTIVES: The study objective was to determine if a daily MVM decreases total invasive cancer among older adults. METHODS: We performed a randomized, double-blind, placebo-controlled, 2-by-2 factorial trial of a daily MVM and cocoa extract for prevention of cancer and cardiovascular disease (CVD) among 21,442 US adults (12,666 women aged ≥65 y and 8776 men aged ≥60 y) free of major CVD and recently diagnosed cancer. The intervention phase was from June 2015 through December 2020. This article reports on the MVM intervention. Participants were randomly assigned to daily MVM or placebo. The primary outcome was total invasive cancer, excluding nonmelanoma skin cancer. Secondary outcomes included major site-specific cancers, total CVD, all-cause mortality, and total cancer risk among those with a baseline history of cancer. RESULTS: During a median follow-up of 3.6 y, invasive cancer occurred in 518 participants in the MVM group and 535 participants in the placebo group (HR: 0.97; 95% CI: 0.86, 1.09; P = 0.57). We observed no significant effect of a daily MVM on breast cancer (HR: 1.06; 95% CI: 0.79, 1.42) or colorectal cancer (HR: 1.30; 95% CI: 0.80, 2.12). We observed a protective effect of a daily MVM on lung cancer (HR: 0.62; 95% CI: 0.42, 0.92). The composite CVD outcome occurred in 429 participants in the MVM group and 437 participants in the placebo group (HR: 0.98; 95% CI: 0.86, 1.12). MVM use did not significantly affect all-cause mortality (HR: 0.93; 95% CI: 0.81, 1.08). There were no safety concerns. CONCLUSIONS: A daily MVM supplement, compared with placebo, did not significantly reduce the incidence of total cancer among older men and women. Future studies are needed to determine the effects of MVMs on other aging-related outcomes among older adults. This trial is registered at www.clinicaltrials.gov as NCT02422745.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ajcn/nqac056

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Screening, randomization, and follow-up of the participants. 1Eligibility was determined by medical history, age, and willingness to forego personal use of cocoa extract and multivitamin pills. 2Eligibility was determined by medical history, age, willingness to forego personal use of cocoa extract and multivitamin pills, caffeine sensitivity, and willingness to limit calcium and vitamin D supplement use. 3Included subjects who never completed the screening phase (n = 2914), eligibility could not be determined (n = 5), and enrollment goal already met (n = 55). 4Included subjects who never completed screening phase (n = 168) and enrollment goal already met (n = 54).
FIGURE 1 Screening, randomization, and follow-up of the participants. 1Eligibility was determined by medical history, age, and willingness to forego personal use of cocoa extract and multivitamin pills. 2Eligibility was determined by medical history, age, willingness to forego personal use of cocoa extract and multivitamin pills, caffeine sensitivity, and willingness to limit calcium and vitamin D supplement use. 3Included subjects who never completed the screening phase (n = 2914), eligibility could not be determined (n = 5), and enrollment goal already met (n = 55). 4Included subjects who never completed screening phase (n = 168) and enrollment goal already met (n = 54).CC BY · PubMed Central
FIGURE 2 HRs and 95% CIs1 for the primary and secondary cancer outcomes, according to randomized assignment, in intention-to-treat analyses. 1Summary statistics were from Cox regression models that stratified baseline hazard functions by cocoa extract trial randomization group, age, sex, and recruitment cohort. Analyses were not adjusted for multiple comparisons. 2This outcome was a composite of invasive cancers of any site other than nonmelanoma skin cancer.
FIGURE 2 HRs and 95% CIs1 for the primary and secondary cancer outcomes, according to randomized assignment, in intention-to-treat analyses. 1Summary statistics were from Cox regression models that stratified baseline hazard functions by cocoa extract trial randomization group, age, sex, and recruitment cohort. Analyses were not adjusted for multiple comparisons. 2This outcome was a composite of invasive cancers of any site other than nonmelanoma skin cancer.CC BY · PubMed Central
FIGURE 3 Cumulative incidence rates of invasive cancer events,1 according to year of follow-up, in multivitamin group and placebo group. 1Primary outcome: a composite of invasive cancers of any site other than nonmelanoma skin cancer. Summary statistics were from Cox regression models that stratified baseline hazard functions by cocoa extract trial randomization group, age, sex, and recruitment cohort (intention-to-treat analyses). P value was for the effect of randomization group, based on a stratified score (log-rank) test.
FIGURE 3 Cumulative incidence rates of invasive cancer events,1 according to year of follow-up, in multivitamin group and placebo group. 1Primary outcome: a composite of invasive cancers of any site other than nonmelanoma skin cancer. Summary statistics were from Cox regression models that stratified baseline hazard functions by cocoa extract trial randomization group, age, sex, and recruitment cohort (intention-to-treat analyses). P value was for the effect of randomization group, based on a stratified score (log-rank) test.CC BY · PubMed Central
FIGURE 4 HRs and 95% CIs1 for secondary cardiovascular disease outcomes, according to randomized assignment, in intention-to-treat analyses. 1Summary statistics were from Cox regression models that stratified baseline hazard functions by cocoa extract trial randomization group, age, sex, and recruitment cohort. Analyses were not adjusted for multiple comparisons. 2This outcome was a composite of myocardial infarction, stroke, cardiovascular death, CABG/PCI, unstable angina including hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty. 3This outcome was a composite of myocardial infarction, stroke, and cardiovascular death. CABG/PCI, coronary artery bypass graft and percutaneous coronary intervention; CVD, cardiovascular disease.
FIGURE 4 HRs and 95% CIs1 for secondary cardiovascular disease outcomes, according to randomized assignment, in intention-to-treat analyses. 1Summary statistics were from Cox regression models that stratified baseline hazard functions by cocoa extract trial randomization group, age, sex, and recruitment cohort. Analyses were not adjusted for multiple comparisons. 2This outcome was a composite of myocardial infarction, stroke, cardiovascular death, CABG/PCI, unstable angina including hospitalization, carotid artery surgery, and peripheral artery surgery or angioplasty. 3This outcome was a composite of myocardial infarction, stroke, and cardiovascular death. CABG/PCI, coronary artery bypass graft and percutaneous coronary intervention; CVD, cardiovascular disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 67 references

Research works printed but not linked: 1

  1. Kantor, 2016, Trends in dietary supplement use among US adults from 1999–2012, JAMA., 316, 1464, 10.1001/jama.2016.14403 · DOI · Paper page

Cited by

See all 51

Metadata

Authors
Sesso, H. D., Rist, P. M., Aragaki, A. K., Rautiainen, S., Johnson, L. G., Friedenberg, G., Copeland, T., Clar, A., Mora, S., Moorthy, M. V., Sarkissian, A., Wactawski-Wende, J., Tinker, L. F., Carrick, W. R., Anderson, G. L., & Manson, J. E.
Affiliations
  • Brigham and Women's Hospital (US)
  • Fred Hutch Cancer Center (US)
Corresponding author
Sesso, Howard D
Venue
The American Journal of Clinical Nutrition
Publisher
Elsevier BV
Published
2022-06
Volume
115
Issue
6
Pages
1501-1510
ISSN
0002-9165 (ISSN-L)
OpenAlex
W4220993553
Cited by
51
References
68
Citations by year
2026: 11 · 2025: 11 · 2024: 12 · 2023: 12 · 2022: 5
FWCI
8.83
Type
journal article
Language
en
Open access
Licence
Locations
  • American Journal of Clinical Nutrition (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • COSMOS (AG050657, AG071611, EY025623, HL157665)
  • National Institutes of Health
  • National Heart, Lung, and Blood Institute
  • U.S. Department of Health and Human Services (75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, 75N92021D00005)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutrition and Health Studies
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
  • Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
Keywords
cancer prevention, cardiovascular disease prevention, older adults, cocoa extract, lung cancer, breast cancer, colorectal cancer, all-cause mortality, COSMOS trial, dietary supplements, calcium, magnesium, potassium, zinc, selenium, iron, nicotinic acid, vitamin C, vitamin B6, vitamin B12
MeSH terms
Aged, Breast Neoplasms, Cacao, Cardiovascular Diseases, Double-Blind Method, Female, Health Promotion, Humans, Male, Vitamins, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. https://app.cochat.ai/papers/10.1093/ajcn/nqac056
The paper
Sesso, H. D., Rist, P. M., Aragaki, A. K., Rautiainen, S., Johnson, L. G., Friedenberg, G., Copeland, T., Clar, A., Mora, S., Moorthy, M. V., Sarkissian, A., Wactawski-Wende, J., Tinker, L. F., Carrick, W. R., Anderson, G. L., & Manson, J. E. (2022). Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial. The American Journal of Clinical Nutrition. https://doi.org/10.1093/ajcn/nqac056

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.